Jim Simons
AYTU icon

Jim Simons’s AYTU BioPharma AYTU Stock Holding History

Jim Simons’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
104,823
+11,100
+12% +$26.2K ﹤0.01% 2856
2026
Q1 		$256K Buy
93,723
+4,100
+5% +$10.5K ﹤0.01% 2856
2025
Q4 		$233K Sell
89,623
-5,500
-6% -$12.3K ﹤0.01% 2848
2025
Q3 		$179K Buy
95,123
+5,210
+6% +$12K ﹤0.01% 3150
2025
Q2 		$196K Buy
89,913
+13,090
+17% +$20.3K ﹤0.01% 3175
2025
Q1 		$92.2K Buy
76,823
+1,400
+2% +$2.04K ﹤0.01% 3210
2024
Q4 		$128K Buy
75,423
+700
+0.9% +$1.28K ﹤0.01% 3247
2024
Q3 		$176K Buy
74,723
+600
+0.8% +$1.55K ﹤0.01% 3151
2024
Q2 		$216K Buy
74,123
+2,800
+4% +$8.45K ﹤0.01% 3022
2024
Q1 		$217K Buy
71,323
+2,400
+3% +$6.87K ﹤0.01% 3201
2023
Q4 		$196K Buy
68,923
+8,200
+14% +$22.6K ﹤0.01% 3139
2023
Q3 		$164K Buy
60,723
+3,400
+6% +$5.95K ﹤0.01% 3134
2023
Q2 		$92K Buy
57,323
+7,700
+16% +$15.1K ﹤0.01% 3495
2023
Q1 		$111K Sell
49,623
-57,416
-54% -$168K ﹤0.01% 3458
2022
Q4 		$405K Buy
107,039
+19,663
+23% +$74K ﹤0.01% 3066
2022
Q3 		$323K Buy
87,376
+34,587
+66% +$262K ﹤0.01% 3182
2022
Q2 		$728K Buy
52,789
+14,516
+38% +$186K ﹤0.01% 2911
2022
Q1 		$827K Buy
38,273
+5,020
+15% +$125K ﹤0.01% 2854
2021
Q4 		$898K Buy
33,253
+223
+0.7% +$9.64K ﹤0.01% 2726
2021
Q3 		$1.9M Buy
33,030
+9,162
+38% +$688K ﹤0.01% 2129
2021
Q2 		$2.39M Buy
23,868
+17,342
+266% +$2.03M ﹤0.01% 2141
2021
Q1 		$992K Buy
+6,526
New +$1.04M ﹤0.01% 2611
2020
Q3 		– Sell
-330
Closed -$94K – 3369
2020
Q2 		$94K Sell
330
-1,198
-78% -$363K ﹤0.01% 3288
2020
Q1 		$458K Buy
+1,528
New +$295K ﹤0.01% 2799
2019
Q1 		– Sell
-476
Closed -$75K – 3445
2018
Q4 		$75K Buy
476
+393
+473% +$86.6K ﹤0.01% 3260
2018
Q3 		$46K Buy
+83
New +$76.8K ﹤0.01% 3288

Other funds holding AYTU

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Crown Advisors Management Larkspur, California $182M AUM 103.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BAM
Bellevue Asset Management Bellevue, Washington $217M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DSC
Daytona Street Capital Saint Louis, Missouri $137M AUM

Jim Simons's AYTU Position: Q2 2026 in Review

Jim Simons increased its AYTU BioPharma (AYTU) stake by 12% in Q2 2026, buying an estimated $26.2K and bringing the position to 104,823 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #2856.

Jim Simons first reported a position in AYTU in Q3 2018 and has held it in 26 quarters since. The position peaked at $2.39M in Q2 2021. 25 funds tracked by Wall St. Rank hold AYTU as of Q2 2026.

  • Jim Simons held 104,823 shares of AYTU BioPharma worth $225K as of Q2 2026.
  • Jim Simons bought 11,100 AYTU BioPharma shares in Q2 2026, an estimated $26.2K.
  • AYTU BioPharma made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2856 holding.
  • Jim Simons first reported a position in AYTU BioPharma in Q3 2018 and has held it in 26 quarters since.
  • Jim Simons's AYTU BioPharma position peaked at $2.39M in Q2 2021.
  • 25 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.